New SITC Guidelines
The Society for Immunotherapy of Cancer (SITC) has recently published guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma, as part of the Cancer Immunotherapy Guidelines series.
These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
.png)
No hay comentarios:
Publicar un comentario